Skip to main content
THERACRYF PLC logo

THERACRYF PLC — Investor Relations & Filings

Ticker · TCF ISIN · GB00BSVYN304 LEI · 213800NO3E6TSTQO8K20 IL Professional, scientific and technical activities
Open in API
Filings indexed 361 across all filing types
Latest filing 2025-05-22 Major Shareholding Noti…
Country GB United Kingdom
Listing IL TCF

About THERACRYF PLC

https://theracryf.com/

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is filed under 'RNS Number : 8274J' on '22 May 2025'. This form is used to report changes in significant share ownership, specifically detailing the acquisition or disposal of voting rights and the resulting percentage held by the notifying party (Northern Standard Limited). This directly corresponds to the definition of a Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content is a mandatory regulatory disclosure about share ownership thresholds, making MRQ the most precise classification over the general RNS fallback.
2025-05-22 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction involving a person discharging managerial responsibilities (PDMR), specifically a Non-Executive Director (Mr. Edward Wardle). It explicitly references 'Director/PDMR Dealings' in the title and provides the required disclosure table under Article 19(1) of the Market Abuse Regulation (MAR). This fits the definition of a Director's Dealing (DIRS) filing.
2025-05-22 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains an 'RNS Number'. It details changes in voting rights held by a shareholder ('Spreadex LTD') crossing a notification threshold, referencing specific regulatory fields like DTR5.1 and DTR5.3.1R. This structure is characteristic of mandatory regulatory disclosures concerning significant ownership changes, which falls under the category of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the content is specific enough to warrant the MRQ classification over the general RNS fallback.
2025-05-16 English
Master Service Agreement signed for Ox-1 programme
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces that TheraCryf plc has signed a Master Service Agreement (MSA) with Pharmaron to progress a specific drug development program. This is a corporate operational update regarding a business partnership and development strategy, which does not fit into specific categories like financial reports, dividends, or director dealings. Therefore, it is classified as a general regulatory announcement.
2025-05-12 English
Board Appointment, Grant of Options, PDMR Dealing
Director's Dealing Classification · 98% confidence The document is an official regulatory announcement from TheraCryf plc regarding a board appointment, the grant of share options, and PDMR (Person Discharging Managerial Responsibility) dealings. It includes detailed tables of shareholdings and specific MAR (Market Abuse Regulation) disclosure forms for director transactions. While it contains information about director dealings (DIRS), the document is a comprehensive announcement covering multiple corporate events (board appointment, share issuance, and option grants) rather than a standalone notification of a single trade. Given the breadth of the announcement and the inclusion of regulatory disclosure forms, it is best classified as a Director's Dealing (DIRS) filing, as the core regulatory purpose of the release is to satisfy the disclosure requirements for PDMR transactions.
2025-05-01 English
Investor webinar
Regulatory Filings Classification · 98% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service) with the RNS Number 1307C. The content explicitly states that it is a 'non-regulatory announcement' and details an upcoming 'Investor Webinar' scheduled for April 2, 2025, hosted by the CEO and Chair to discuss company programs following a recent fundraise. This is not a full financial report (like 10-K or IR), nor is it a specific regulatory filing like a Director's Dealing or a Dividend Notice. It is an announcement about an event intended for investors, which falls under general corporate communications. Since it is a formal announcement distributed through the RNS system and doesn't fit the specific categories like ER, IP, or AGM-R (which is for materials *from* the AGM), the most appropriate general category for a non-regulatory, non-financial results announcement distributed via RNS is the fallback category, Regulatory Filings (RNS), as it is a standard RNS distribution notice.
2025-03-26 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.